The estimated Net Worth of Michael Ackermann is at least $39.2 Million dollars as of 15 June 2022. Michael Ackermann owns over 4,257 units of Tarsus Pharmaceuticals stock worth over $38,423,081 and over the last 5 years Michael sold TARS stock worth over $752,360.
Michael has made over 10 trades of the Tarsus Pharmaceuticals stock since 2021, according to the Form 4 filled with the SEC. Most recently Michael exercised 4,257 units of TARS stock worth $135,373 on 15 June 2022.
The largest trade Michael's ever made was buying 100,000 units of Tarsus Pharmaceuticals stock on 5 May 2022 worth over $1,350,000. On average, Michael trades about 8,895 units every 21 days since 2019. As of 15 June 2022 Michael still owns at least 1,208,273 units of Tarsus Pharmaceuticals stock.
You can see the complete history of Michael Ackermann stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE, CA, 92618.
Over the last 4 years, insiders at Tarsus Pharmaceuticals have traded over $38,362,333 worth of Tarsus Pharmaceuticals stock and bought 1,047,656 units worth $16,525,269 . The most active insiders traders include Investments, Lpwong Roderic..., Capital Ix, Llc Vivo Capita..., and William J Phd Link. On average, Tarsus Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $729,047. The most recent stock trade was executed by William J Phd Link on 12 August 2024, trading 35,000 units of TARS stock currently worth $912,800.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals executives and other stock owners filed with the SEC include: